Human ex vivo gene therapy protocols have been used successfully to treat a variety of genetic disorders, infectious diseases, and cancer. Murine oncoretroviruses (specifically, gammaretroviruses) have served as the primary gene delivery vehicles for these trials. However, in some cases, such vectors have been associated with insertional mutagenesis. As a result, alternative vector platforms such as lentiviral vectors (LVVs) are being developed. LVVs may provide advantages compared with gammaretroviral vectors, including the ability to transduce large numbers of nondividing cells, resistance to gene silencing, and a potentially safer integration profile. The aim of this study was to develop a simplified process for the rapid production of clinical-grade LVVs. To that end, we used a self-inactivating bicistronic LVV encoding an MART (melanoma antigen recognized by T cells)-1-reactive T cell receptor containing oPRE, an optimized and truncated version of woodchuck hepatitis virus posttranslational regulatory element (wPRE). Using our simplified clinical production process, 293T cells were transiently transfected in roller bottles. The LVV supernatant was collected, treated with Benzonase, and clarified by modified step filtration. LVV produced in this manner exhibited titers and a biosafety profile similar to those of cGMP (current Good Manufacturing Practices) LVVs previously manufactured at the Indiana University Vector Production Facility in support of a phase I/II clinical trial. We describe a simple, efficient, and low-cost method for the production of clinical-grade LVV for ex vivo gene therapy protocols.
Yang and colleagues describe a simple, efficient and low-cost process for the rapid production of clinical-grade lentiviral vectors (LVVs). 293T cells were transiently transfected in roller bottles, and supernatants were subsequently treated with Benzonase and clarified by modified step-filtration. LVV titers and biosafety profiles were similar to those of LVVs previously manufactured in support of a phase I/II clinical trial.
Get full access to this article
View all access options for this article.
References
1.
AiutiA., ShimonS., AkerM.et al.2002. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science, 296:2410–2413.
2.
AnsorgeS., LanthierS., TransfiguracionJ.et al.2009. Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures. J. Gene Med., 11:868–876.
3.
BlaeseR.M., CulverK.W., MillerA.D.et al.1995. T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science, 270:475–480.
4.
BouchardM.J., SchneiderR.J.2004. The enigmatic X gene of hepatitis B virus. J. Virol., 78:12725–12734.
5.
BrentjensR.J., RivièreI., ParkJ.H.et al.2011. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood, 118:4817–4828.
6.
CavalieriS., CazzanigaS., GeunaM.et al.2003. Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood, 102:497–505.
7.
Cavazzana-CalvoM., Jacein-BeyS., de Saint BasileG.et al.2000. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science, 288:669–672.
8.
Cavazzana-CalvoM., PayenE., NegreO.et al.2010. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature, 467:318–322.
9.
ChangA.H., SadelainM.2007. The genetic engineering of hematopoietic stem cells: The rise of lentiviral vectors, the conundrum of the LTR, and the promise of lineage-restricted vectors. Mol. Ther., 15:445–456.
10.
CharrierS., FerrandM., ZerbatoM.et al.2011. Quantification of lentiviral vector copy numbers in individual hematopoietic colony-forming cells shows vector dose-dependent effects on the frequency and level of transduction. Gene Ther., 18:479–487.
11.
DeglonN., TsengJ.L., BensadounJ.-C.et al.2000. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum. Gene Ther., 11:179–190.
12.
DudleyM.E., YangJ.C., SherryR.et al.2008. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol., 26:5233–5239.
13.
DullT., ZuffereyR., KellyM.et al.1998. A third-generation lentivirus vector with a conditional packaging system. J. Virol., 72:8463–8471.
14.
FeldmanS.A., GoffS.L., XuH.et al.2011. Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a “modified” step-filtration process for clearance of packaging cells. Hum. Gene Ther., 22:107–115.
15.
GasparH.B., ParsleyK.L., HoweS.et al.2004. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet, 364:2181–2187.
16.
GoffS., JohnsonL., BlackM.et al.2010. Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion. Cancer Immunol. Immunother., 59:1551–1560.
17.
GriffithsE.1997. WHO Expert Committee on Biological Standardization: Highlights of the meeting of October 1996. Biologicals, 25:359–362.
18.
Hacein-Bey-AbinaS., von KalleC., SchmidtM.et al.2003. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med., 348:255–256.
19.
HeslopH.E., NgC.Y.C., LiC.et al.1996. Long-term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med., 2:551–555.
20.
IkawaM., TanakaM., KaoW.W.-Y., VermaI.M.2003. Generation of transgenic mice using lentiviral vectors: A novel preclinical assessment of lentiviral vectors for gene therapy. Mol. Ther., 8:666–673.
JohnsonL.A., HeemskerkB., PowellD.J.Jr.et al.2006. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J. Immunol., 177:6548–6559.
23.
JohnsonL.A., MorganR.A., DudleyM.E.et al.2009. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood, 114:535–546.
24.
JonesS., PengP.D., YangS.et al.2009. Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Hum. Gene Ther., 20:630–640.
25.
KafriT., van PraagH., OuyangL.et al.1999. A packaging cell line for lentivirus vectors. J. Virol., 73:576–584.
26.
KalosM., LevineB.L., PorterD.L.et al.2011. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med., 3:95ra73.
27.
KochenderferJ.N., WilsonW.H., JanikJ.E.et al.2010. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood, 116:4099–4102.
28.
KochenderferJ.N., DudleyM.E., MaricI.et al.2011. Dramatic regression of chronic lymphocytic leukemia in the first patient treated with donor-derived genetically-engineered anti-CD19-chimeric-antigen-receptor-expressing T cells after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant., 17:S158–S158.
29.
LizéeG., AertsJ.L., GonzalesM.I.et al.2003. Real-time quantitative reverse transcriptase-polymerase chain reaction as a method for determining lentiviral vector titers and measuring transgene expression. Hum. Gene Ther., 14:497–507.
30.
MertenO.-W., CharrierS., LaroudieN.et al.2011. Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum. Gene Ther., 22:343–356.
31.
MontiniE., CesanaD., SchmidtM.et al.2006. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol., 24:687–696.
32.
MorganR.A., DudleyM.E., WunderlichJ.R.et al.2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 314:126–129.
33.
ParkhurstM.R., YangJ.C., LanganR.C.et al.2011. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther., 19:620–626.
34.
PfeiferA., IkawaM., DaynY., VermaI.M.2002. Transgenesis by lentiviral vectors: Lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. Proc. Natl. Acad. Sci. U.S.A., 99:2140–2145.
35.
PorterD.L., LevineB.L., KalosM.et al.2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med., 365:725–733.
36.
RamezaniA., HawleyT.S., HawleyR.G.2000. Lentiviral vectors for enhanced gene expression in human hematopoietic cells. Mol. Ther., 2:458–469.
37.
RobbinsP.F., MorganR.A., FeldmanS.A.et al.2011. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol., 29:917–924.
38.
RosenbergS.A., YangJ.C., SherryR.M.et al.2011. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res., 17:4550–4557.
39.
SastryL., XuY., CooperR.et al.2004. Evaluation of plasmid DNA removal from lentiviral vectors by Benzonase treatment. Hum. Gene Ther., 15:221–226.
40.
SavoldoB., RamosC.A., LiuE.et al.2011. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest., 121:1822–1826.
41.
SchambachA., BohneJ., BaumC.et al.2005. Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther., 13:641–645.
42.
SchambachA., MuellerD., GallaM.et al.2006. Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors. Gene Ther., 13:1524–1533.
43.
SchweizerM., MertenO.-W.2010. Large-scale production means for the manufacturing of lentiviral vectors. Curr. Gene Ther., 10:474–486.
44.
SeguraM.M., GarnierA., DurocherY.et al.2010. New protocol for lentiviral vector mass production. Lentivirus Gene Engineering Protocols. FedericoM.Humana Press: New York, 39–52.
45.
SeguraM.M., KamenA.A., GarnierA.2011. Overview of Current Scalable Methods for Purification of Viral Vectors. In Viral Vectors for Gene Therapy. MertenO.-W., Al-RubeaiM.Humana Press, 89–116.
46.
ShawK.L., KohnD.B.2011. A tale of two SCIDs. Sci. Transl. Med., 3:97ps36.
47.
StewartH.J., Fong-WongL., StricklandI.et al.2011. A stable producer cell line for the manufacture of a lentiviral vector for gene therapy of Parkinson's disease. Hum. Gene Ther., 22:357–369.
48.
ThromR.E., OumaA.A., ZhouS.et al.2009. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood, 113:5104–5110.
49.
TopalianS., SolomonD., RosenbergS.1989. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol., 142:3714–3725.
50.
WalterE.A., GreenbergP.D., GilbertM.J.et al.1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med., 333:1038–1044.
51.
WiznerowiczM., TronoD.2005. Harnessing HIV for therapy: Basic research and biotechnology. Trends Biotechnol., 23:42–47.
WuX., LiY., CriseB., BurgessS.M.2003. Transcription start regions in the human genome are favored targets for MLV integration. Science, 300:1749–1751.
54.
YangS., CohenC.J., PengP.D.et al.2008a. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther., 15:1411–1423.
55.
YangS., RosenbergS.A., MorganR.A.2008b. Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells. J. Immunother., 31:830–839.
56.
ZuffereyR., DonelloJ.E., TronoD., HopeT.J.1999. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol., 73:2886–2892.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
